Cannell Capital’s Vigil Neuroscience VIGL Stock Holding History

Cannell Capital’s Portfolio VIGL Stock Details VIGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-8,044	Closed	-$78.8K	–	83
2023 Q1	$78.8K	Hold	8,044	–	–	0.02%	66
2022 Q4	$101K	Hold	8,044	–	–	0.02%	61
2022 Q3	$73K	Buy	8,044 +4,408	+121%	+$32.3K	0.02%	65
2022 Q2	$9K	Buy	+3,636	New	+$14.4K	﹤0.01%	87

Other funds holding VIGL

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

Northpond Ventures Bethesda, Maryland $43.7M AUM 27.27% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Cannell Capital's VIGL Position: Q2 2023 in Review

Cannell Capital sold out of Vigil Neuroscience (VIGL) in Q2 2023, closing a stake of 8,044 shares — an estimated $78.8K sold.

Cannell Capital first reported a position in VIGL in Q2 2022 and held it in 4 quarters. The position peaked at $101K in Q4 2022. 47 funds tracked by Wall St. Rank hold VIGL as of Q2 2023.

Cannell Capital reported no remaining Vigil Neuroscience position as of Q2 2023 after selling out during the quarter.
Cannell Capital sold 8,044 Vigil Neuroscience shares in Q2 2023, an estimated $78.8K.
Cannell Capital first reported a position in Vigil Neuroscience in Q2 2022 and held it in 4 quarters.
Cannell Capital's Vigil Neuroscience position peaked at $101K in Q4 2022.
47 funds tracked by Wall St. Rank held Vigil Neuroscience as of Q2 2023.

Based on Cannell Capital's 13F filing for Q2 2023, filed 14 Aug 2023.